Adaptive Biotechnologies

Public

Seattle, WashingtonBiotechhttps://www.adaptivebiotech.com/

Last Round

Debt

Sep 12, 2022

Total Funding Raised

$1.21B

Company Overview

Adaptive Biotechnologies is a biotechnology company that develops an immune medicine platform for the diagnosis and treatment of various diseases, including cancer and autoimmune conditions.

Sector

Biotech

AI Layer

Application

Keywords

minimal residual diseaseMRDclonoSEQimmune repertoire sequencingcancer diagnosticsimmunomicsT-cell receptorimmune medicinebiomarker discoveryliquid biopsyDNA sequencingdrug discoveryclinical diagnosticsprecision oncologyAI-driven biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adaptive Biotechnologies Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Adaptive Biotechnologies Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Debt	Sep 12, 2022
Follow-on Offering	Jul 15, 2020
IPO Announced	Jun 26, 2019
Series F Extension	Dec 11, 2017
Series F	May 6, 2015
Series E	Jan 7, 2015

View all Funding Rounds

Key People

Founding team and executive leadership

Harlan Robins

co-founder and chief Scientific Officer

Founding Team

Chad Robins

CEO & Co-Founder

Founding Team

Julie Rubinstein

President and Chief Operating Officer

Executive Team

Kyle Piskel

Chief Financial Officer

Executive Team

View all key people

Adaptive Biotechnologies Investors

Notable investors and investment history

Investor	Rounds
Guggenheim Securities	IPO, Follow-on Offering
BofA Securities	Follow-on Offering
OrbiMed	Debt
BD Biosciences	Series F
Walden Venture Capital	Series A
Viking Global Investors	Series F, Series F Extension, Series C
Senator Investment Group	Series F

View all Investors

Adaptive Biotechnologies Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Adaptive Biotechnologies Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersSeattle, Washington

Employee Range652

Year Founded2009

Last FundingSep 12, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.